Zelluna Immunotherapy, a biotechnology company specializing in T-cell receptor (TCR) immunotherapies, has announced the appointment of Dr. Namir Hassan as chief scientific officer (CSO).
Novartis announced today the appointment of Dr Klaus Moosmayer as Chief Ethics, Risk and Compliance Officer. He will report to Vas Narasimhan, M.D., CEO of Novartis and become a member of the Executive Committee of Novartis (ECN). Dr. Moosmayer will join Novartis on December 1, 2018 and will be based in Basel, Switzerland. He succeeds Shannon Thyme Klinger who was recently appointed Group General Counsel.
Sphere Fluidics, a company providing single cell analysis systems underpinned by its patented picodroplet technology, announced today that Tris Vaughan, PhD FRSB has joined its scientific advisory board (SAB).
Cellectis, a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), announced today the appointment of Dr. Stefan Scherer, M.D., Ph.D., to the role of Senior Vice President Clinical Development and Deputy Chief Medical Officer. Dr. Scherer joins Cellectis from Novartis Pharmaceuticals Corporation, where he was the Head of Early Development, Strategy and Innovation for U.S. Oncology.
Cell Medica, a company active in the development, manufacture and marketing of personalised cellular immunotherapeutics for the treatment of cancer, has appointed Chris Nowers as Chief Executive Officer and Executive Director.
Pascal Schmidt appointed CFO as Vienna based biotech firm Marinomedas of August 1 2018.
Morphosys has named Jennifer Herron President of MorphoSys US Inc. to build up sales presence overseas.
The Board of Directors of the company has appointed Dr. Deborah Dunsire as new president and CEO of Lundbeck. Deborah Dunsire will take up her new position on 1 September 2018.
EuropaBios Executive Board and General Assembly of Members this week confirmed the appointment of Tjerk de Ruiter as Chairman of the association.
Symcel has announced the appointment of two new board members; Erik Walldén and Stefan Löfås. Both will play a key role in the companys corporate strategy to grow business in the research market and develop solutions for clinical diagnostics.